Abstract:Introduction: The concurrence of intellectual disability/global developmental delay and epilepsy (ID/GDD-EP) is very common in the pediatric population. The etiologies for both conditions are complex and largely unknown. The predictors of significant copy number variations (CNVs) are known for the cases with ID/GDD, but unknown for those with exclusive ID/GDD-EP. Importantly, the known predictors are largely from the same ethnic group; hence, they lack replication. Purpose: We aimed to determine and investigate the diagnostic yield of CNV tests, new causative CNVs, and the independent predictors of significant CNVs in Chinese children with unexplained ID/GDD-EP. Materials and methods: A total of 100 pediatric patients with unexplained ID/GDD-EP and 1,000 healthy controls were recruited. The American College of Medical Genetics guideline was used to classify the CNVs. Additionally, clinical information was collected and compared between those with significant and non-significant CNVs. Results: Twenty-eight percent of the patients had significant CNVs, 16% had variants of unknown significance, and 56% had non-significant CNVs. In total, 31 CNVs were identified in 28% (28/100) of cases: 25 pathogenic and 6 likely pathogenic. Eighteen known syndromes were diagnosed in 17 cases. Thirteen rare CNVs (8 novel and 5 reported in literature) were identified, of which three spanned dosage-sensitive genes: 19q13.2 deletion (ATP1A3), Xp11.4-p11.3 deletion (CASK), and 6q25.3-q25.3 deletion (ARID1B). By comparing clinical features in patients with significant CNVs against those with non-significant CNVs, a statistically significant association was found between the presence of significant CNVs and speech and language delay for those aged above 2 years and for those with facial malformations, microcephaly, congenital heart disease, fair skin, eye malformations, and mega cisterna magna. Multivariate logistic regression analysis allowed the identification of two independent significant CNV predictors, which are eye malformations and facial malformations. Conclusion: Our study supports the performance of CNV tests in pediatric patients with unexplained ID/GDD-EP, as there is high diagnostic yield, which informs genetic counseling. It adds 13 rare CNVs (8 novel), which can be accountable for both conditions. Moreover, congenital eye and facial malformations are clinical markers that can aid clinicians to understand which patients can benefit from the CNV testing and which will not, thus helping patients to avoid unnecessary and expensive Wets.

The combination of whole-exome sequencing and copy number variation sequencing enables the diagnosis of rare neurological disorders.

Application of a Next-Generation Sequencing (NGS) Panel in Newborn Screening Efficiently Identifies Inborn Disorders of Neonates

A Multicenter Prospective Study of Next-Generation Sequencing-Based Newborn Screening for Monogenic Genetic Diseases in China

Diagnostic and Clinical Utility of Whole Genome Sequencing in a Cohort of Undiagnosed Chinese Families with Rare Diseases

Using Next-Generation Sequencing As A Genetic Diagnostic Tool in Rare Autosomal Recessive Neurologic Mendelian Disorders

Genetic Analysis of Children with Unexplained Developmental Delay And/or Intellectual Disability by Whole-Exome Sequencing.

Next Generation Sequencing in Children with Unexplained Epilepsy: A Retrospective Cohort Study.

Whole genome sequencing for copy number variant detection to improve diagnosis and management of rare diseases

Clinical exome sequencing as the first-tier test for diagnosing developmental disorders covering both CNV and SNV: a Chinese cohort

Diagnostic Yield and Novel Candidate Genes for Neurodevelopmental Disorders by Exome Sequencing in an Unselected Cohort with Microcephaly

Detection of Disease-Causing SNVs/Indels and CNVs in Single Test Based on Whole Exome Sequencing: A Retrospective Case Study in Epileptic Encephalopathies

Clinical exome sequencing in the diagnosis of pediatric neuromuscular disease

Clinical utility in infants with suspected monogenic conditions through next-generation sequencing.

The application of whole-exome sequencing in the early diagnosis of rare genetic diseases in children: a study from Southeastern China

High Diagnostic Yield and Clinical Utility of Next-Generation Sequencing in Children with Epilepsy and Neurodevelopmental Delays: A Retrospective Study

Rare Copy Number Variations and Predictors in Children With Intellectual Disability and Epilepsy.

Copy number variation analysis in 83 children with early-onset developmental and epileptic encephalopathy after targeted resequencing of a 109-epilepsy gene panel

Utility of genome sequencing in exome‐negative pediatric patients with neurodevelopmental phenotypes

Exome copy number variant detection, analysis, and classification in a large cohort of families with undiagnosed rare genetic disease

Utility of next generation sequencing in paediatric neurological disorders: experience from South Africa

Next-generation Sequencing Improves Treatment Efficacy and Reduces Hospitalization in Children with Drug-Resistant Epilepsy